MarketBeat
09 Aug 2026, 20:04 UTC · 3h ago
Vaxart Q2 Earnings Call Highlights
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
09 Aug 2026, 20:04 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Vaxart reported positive 12-month safety data from the 400-participant Sentinel cohort of its Phase II-B COVID-19 vaccine trial, with no vaccine-related serious health complications. — Positive safety data is a critical de-risking milestone for any biotech candidate, though the small cohort size limits the immediate impact on efficacy expectations.
+0.60The company expects to disclose top-line data from the larger 5,000-participant main COVID-19 cohort in the first half of 2027. — This establishes the timeline for the primary value-inflection catalyst, signaling a long wait for definitive efficacy results.
+0.40Vaxart secured a $29 million contract modification from BARDA to fund expanded scientific analyses and study execution. — Non-dilutive government funding extends the company's runway and validates the project's importance to federal health agencies.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
Vaxart has removed the projected norovirus vaccine timeline from its presentation as the Phase II start is contingent on securing funding. — This indicates a lack of immediate funding for a key pipeline asset and suggests an increased reliance on finding a commercial partner.
-0.30Vaxart ended Q2 2026 with $64 million in cash, providing a runway into the second quarter of 2027. — Provides a clear liquidity window that roughly aligns with the expected top-line data release, reducing immediate bankruptcy risk.
+0.10Which stocks this story touches
Reported positive safety data for its COVID-19 vaccine and secured $29 million in additional BARDA funding.
Mentioned in the context of extending enrollment in its norovirus study, which Vaxart views as a potential competitive advantage.
Mentioned as a collaboration partner providing licensing revenue to Vaxart.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
2h ago
